Azenta, Inc. (NASDAQ:AZTA) Given Average Rating of “Hold” by Brokerages

by · The Cerbat Gem

Azenta, Inc. (NASDAQ:AZTA – Get Free Report) has received an average recommendation of “Hold” from the seven brokerages that are covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 12-month target price among analysts that have covered the stock in the last year is $41.20.

A number of analysts have commented on the company. Needham & Company LLC restated a “buy” rating and issued a $37.00 price target on shares of Azenta in a research report on Monday. Weiss Ratings raised Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 26th.

Get Our Latest Stock Report on AZTA

Azenta Stock Up 1.3%

NASDAQ AZTA opened at $33.63 on Friday. The company has a 50-day moving average price of $30.84 and a 200-day moving average price of $25.46. Azenta has a 52 week low of $15.93 and a 52 week high of $41.73. The firm has a market capitalization of $1.47 billion, a P/E ratio of -12.18 and a beta of 1.39.

Azenta (NASDAQ:AZTA – Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported $0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.05. Azenta had a negative net margin of 20.63% and a positive return on equity of 1.18%. The company had revenue of $161.18 million during the quarter, compared to analyst estimates of $149.31 million.

Hedge Funds Weigh In On Azenta

Hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of Azenta during the 2nd quarter worth $192,152,000. Conestoga Capital Advisors LLC lifted its holdings in shares of Azenta by 116.1% during the 1st quarter. Conestoga Capital Advisors LLC now owns 2,844,546 shares of the company’s stock valued at $60,105,000 after purchasing an additional 1,528,145 shares during the last quarter. Front Street Capital Management Inc. acquired a new stake in Azenta in the second quarter worth about $33,212,000. American Capital Management Inc. purchased a new stake in Azenta during the 2nd quarter worth approximately $27,089,000. Finally, Bank of America Corp DE acquired a new position in shares of Azenta in the 2nd quarter valued at $17,058,000. 99.08% of the stock is currently owned by institutional investors.

Azenta Company Profile

(Get Free Report)

Azenta, Inc (NASDAQ: AZTA) is a life sciences company that provides solutions for the management, storage, and analysis of biological samples. Its customers include pharmaceutical and biotechnology companies, academic and government research institutions, clinical research organizations, and other organizations involved in drug discovery, clinical research, and genomic analysis.

The company offers automated sample-management systems, ultra-low-temperature and cryogenic storage equipment, laboratory automation, consumables, and software for tracking and managing biological specimens.

Featured Articles